Armata Pharmaceuticals Inc. Common Stock (ARMP)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-and-Graham-style investor, I look first for a durable business with earnings and a margin of safety. Armata is a clinical-stage phage-therapeutics company with 61 employees, no reported revenue in the filed periods I was given, and no Lynch category because it has lost money in each of the last four years. In fiscal 2023, the year ended 2023-12-31, it reported a net loss of $69.0 million and diluted EPS of $-1.91; in fiscal 2024, a net loss of $18.9 million and EPS of $-0.89; and in fiscal 2025, a net loss of $173.8 million and EPS of $-4.80. Quarterly results are volatile: fiscal Q1 2026, ended 2026-03-31, had a net loss of $115.3 million and EPS of $-3.16, while fiscal Q2 2026, ended 2026-06-30, showed net income of $74.1 million but diluted EPS of $-0.27. Trailing free cash flow is -$24.5 million, a FairStock-calculated FCF yield of -21.2%, so the company is consuming cash. FairStock also assigns a Piotroski score of 0/9 and an Altman Z-Score of -12.25, both consistent with financial distress or at least heavy dependence on external capital. At the 2026-10-13 close of $3.10, market cap is $115.3 million. The P/E is -0.59, P/B is N/A, and ROCE is -25.83%; there is no earnings-based valuation anchor. Shares are near the low end of the 52-week range of $3.01 to $16.34, but a low price is not the same as cheap. Without revenue, profits, or a proven moat, this is a speculative clinical bet, not a Graham bargain.

In plain English: Armata Pharmaceuticals is a small clinical-stage biotech working on treatments that use bacteriophages to fight antibiotic-resistant infections. It has no reported revenue and has been losing money, with negative cash flow and weak financial scores. At $3.10, the stock is near its 52-week low, but without profits or sales the price does not look cheap on the business numbers; it looks speculative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer